Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Amortization of Deferred Charges (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 13 years of Amortization of Deferred Charges data on record, last reported at $414000.0 in Q3 2025.

  • For Q3 2025, Amortization of Deferred Charges fell 24.86% year-over-year to $414000.0; the TTM value through Sep 2025 reached $2.1 million, up 7.41%, while the annual FY2024 figure was $2.5 million, 4.38% up from the prior year.
  • Amortization of Deferred Charges reached $414000.0 in Q3 2025 per NWBO's latest filing, down from $525000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $1.1 million in Q1 2021 and bottomed at $231000.0 in Q2 2021.
  • Average Amortization of Deferred Charges over 5 years is $589105.3, with a median of $576000.0 recorded in 2024.
  • The widest YoY moves for Amortization of Deferred Charges: up 1307.5% in 2021, down 76.74% in 2021.
  • A 5-year view of Amortization of Deferred Charges shows it stood at $580000.0 in 2021, then grew by 13.79% to $660000.0 in 2022, then plummeted by 44.55% to $366000.0 in 2023, then surged by 134.43% to $858000.0 in 2024, then crashed by 51.75% to $414000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Amortization of Deferred Charges were $414000.0 in Q3 2025, $525000.0 in Q2 2025, and $334000.0 in Q1 2025.